Tobias Bäuerle Selected Research

gallium 68 PSMA-11

10/2019	68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
10/2018	68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tobias Bäuerle Research Topics

Disease

36	Neoplasms (Cancer) 12/2023 - 06/2005
24	Neoplasm Metastasis (Metastasis) 05/2022 - 06/2005
20	Breast Neoplasms (Breast Cancer) 01/2024 - 06/2005
13	Inflammation (Inflammations) 02/2024 - 01/2016
9	Prostatic Neoplasms (Prostate Cancer) 11/2023 - 04/2018
8	Fibrosis (Cirrhosis) 12/2023 - 01/2016
7	Arthritis (Polyarthritis) 02/2024 - 01/2017
4	Carcinoma (Carcinomatosis) 11/2023 - 04/2010
4	Ewing Sarcoma (Sarcoma, Ewing) 11/2021 - 09/2016
4	Osteolysis 06/2012 - 05/2008
3	Atherosclerosis 01/2024 - 02/2016
3	Bone Resorption 11/2020 - 10/2011
3	Chronic Renal Insufficiency 01/2018 - 01/2016
2	Neuroinflammatory Diseases 02/2024 - 01/2021
2	Triple Negative Breast Neoplasms 01/2024 - 03/2023
2	Hypersensitivity (Allergy) 01/2024 - 01/2017
2	Rheumatoid Arthritis 01/2023 - 01/2019
2	Alcoholism (Alcohol Abuse) 01/2023 - 12/2021
2	Systemic Scleroderma (Systemic Sclerosis) 01/2023 - 03/2021
2	Disease Progression 03/2021 - 01/2016
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2021 - 07/2020
2	Multiple Sclerosis 01/2021 - 11/2019
2	Demyelinating Diseases (Demyelinating Disease) 07/2020 - 01/2020
2	Multiple System Atrophy 01/2020 - 01/2016
2	Edema (Dropsy) 11/2019 - 01/2018
2	Nephrocalcinosis 01/2018 - 01/2018
2	Melanoma (Melanoma, Malignant) 05/2016 - 11/2009
1	Experimental Arthritis 02/2024
1	Atherosclerotic Plaque (Atheroma) 01/2024
1	Autoimmune Diseases (Autoimmune Disease) 01/2023
1	Obesity 05/2022
1	Hypoxia (Hypoxemia) 11/2021
1	Nephrogenic Fibrosing Dermopathy 09/2021
1	Interstitial Lung Diseases (Interstitial Lung Disease) 03/2021

Drug/Important Bio-Agent (IBA)

9	Proteins (Proteins, Gene)FDA Link 02/2024 - 03/2006
7	AntigensIBA 01/2022 - 04/2018
6	Contrast MediaIBA 01/2024 - 08/2012
6	IntegrinsIBA 01/2018 - 01/2011
5	Biomarkers (Surrogate Marker)IBA 11/2023 - 02/2010
5	technetium 99m 1- (1- (2- (bis(carboxymethyl)amino)- 2- oxoethyl)- 1H- imidazol- 2- yl)- 2- ((1- (2- (bis(carboxymethyl)amino)- 2- oxoethyl)- 1H- imidazol- 2- yl)methyl)- 9,14- dioxo- 2,8,13,15- tetraazaoctadecane- 7,12,16,18- tetracarboxylic acid)IBA 08/2020 - 04/2018
5	Integrin-Binding SialoproteinIBA 06/2012 - 06/2005
4	CytokinesIBA 01/2023 - 10/2018
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 05/2008
4	CilengitideIBA 04/2013 - 01/2011
3	Phenobarbital (Luminal)FDA Link 01/2024 - 06/2013
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 05/2016
3	Circulating Tumor DNAIBA 11/2021 - 01/2020
3	LigandsIBA 01/2021 - 04/2018
3	OsteopontinIBA 05/2016 - 04/2010
3	Zoledronic Acid (Zometa)FDA Link 09/2014 - 01/2007
3	Sunitinib (Sutent)FDA Link 09/2014 - 06/2010
2	Interleukin-17 (Interleukin 17)IBA 02/2024 - 01/2019
2	RNA (Ribonucleic Acid)IBA 02/2024 - 01/2019
2	Dextrans (Dextran)FDA Link 01/2024 - 01/2018
2	CholesterolIBA 01/2024 - 10/2020
2	CollagenIBA 12/2023 - 04/2013
2	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 01/2023 - 12/2021
2	AntibodiesIBA 01/2023 - 01/2019
2	Immunoglobulin G (IgG)IBA 01/2023 - 01/2018
2	FibrinIBA 06/2022 - 10/2020
2	PPAR gammaIBA 05/2022 - 12/2021
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 05/2022 - 01/2011
2	bisphenol AIBA 05/2022 - 12/2021
2	Complement System Proteins (Complement)IBA 11/2021 - 01/2017
2	Tumor Biomarkers (Tumor Markers)IBA 11/2021 - 09/2016
2	InflammasomesIBA 11/2021 - 01/2018
2	GadoliniumIBA 09/2021 - 02/2020
2	Prostate-Specific Antigen (Semenogelase)IBA 12/2019 - 10/2019
2	N,N'- bis(2- hydroxy- 5- (ethylene- beta- carboxy)benzyl)ethylenediamine N,N'-diacetic acidIBA 10/2019 - 10/2018
2	gallium 68 PSMA-11IBA 10/2019 - 10/2018
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 01/2017
2	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 06/2012
2	EnzymesIBA 01/2019 - 11/2009
2	Therapeutic UsesIBA 01/2018 - 02/2016
2	Calcium OxalateIBA 01/2018 - 01/2018
2	salicylhydroxamic acid (SHAM)IBA 07/2012 - 06/2010
2	Bevacizumab (Avastin)FDA Link 02/2010 - 05/2008
1	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 02/2024
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2024
1	ferric ferrocyanide (Prussian blue)FDA Link 01/2024
1	ferric oxide (iron oxide)IBA 01/2024
1	Ferrosoferric Oxide (Magnetite)FDA Link 01/2024
1	Hormones (Hormone)IBA 03/2023
1	AutoantibodiesIBA 01/2023
1	A-factor (Streptomyces)IBA 01/2023
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2023
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2023
1	polycaprolactoneIBA 06/2022
1	AlginatesIBA 06/2022
1	Glucose (Dextrose)FDA LinkGeneric 05/2022
1	TOR Serine-Threonine KinasesIBA 11/2021
1	68Ga-FAPIIBA 03/2021
1	Prolyl OligopeptidasesIBA 03/2021
1	abemaciclibIBA 01/2021
1	LuciferasesIBA 01/2021

Therapy/Procedure

24	Therapeutics 06/2022 - 10/2009
4	Aftercare (After-Treatment) 01/2021 - 10/2009
2	Radiotherapy 08/2020 - 01/2019
1	Intranasal Administration 02/2024
1	Transplantation 06/2022